Alexion Pharmaceuticals, Inc. (ALXN) Stake Decreased by Itau Unibanco Holding S.A.

Itau Unibanco Holding S.A. lessened its holdings in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 31.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,982 shares of the biopharmaceutical company’s stock after selling 893 shares during the period. Itau Unibanco Holding S.A.’s holdings in Alexion Pharmaceuticals were worth $237,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Ameriprise Financial Inc. raised its holdings in shares of Alexion Pharmaceuticals by 3.5% during the third quarter. Ameriprise Financial Inc. now owns 6,390,301 shares of the biopharmaceutical company’s stock valued at $896,491,000 after buying an additional 215,005 shares during the last quarter. Jennison Associates LLC raised its holdings in Alexion Pharmaceuticals by 720.0% during the third quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock worth $748,116,000 after purchasing an additional 4,682,336 shares in the last quarter. UBS Asset Management Americas Inc. raised its holdings in Alexion Pharmaceuticals by 10.3% during the fourth quarter. UBS Asset Management Americas Inc. now owns 1,871,548 shares of the biopharmaceutical company’s stock worth $223,818,000 after purchasing an additional 174,606 shares in the last quarter. Wells Fargo & Company MN raised its holdings in Alexion Pharmaceuticals by 32.7% during the third quarter. Wells Fargo & Company MN now owns 1,558,531 shares of the biopharmaceutical company’s stock worth $218,647,000 after purchasing an additional 383,713 shares in the last quarter. Finally, Bank of Montreal Can raised its holdings in Alexion Pharmaceuticals by 21.4% during the fourth quarter. Bank of Montreal Can now owns 1,521,834 shares of the biopharmaceutical company’s stock worth $181,998,000 after purchasing an additional 268,053 shares in the last quarter. 95.38% of the stock is currently owned by institutional investors.

In other Alexion Pharmaceuticals news, CEO Ludwig Hantson sold 13,245 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $116.31, for a total transaction of $1,540,525.95. Following the transaction, the chief executive officer now directly owns 131,425 shares in the company, valued at approximately $15,286,041.75. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Heidi L. Wagner sold 655 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $117.26, for a total transaction of $76,805.30. Following the transaction, the senior vice president now owns 32,635 shares in the company, valued at $3,826,780.10. The disclosure for this sale can be found here. Insiders sold 28,930 shares of company stock worth $3,378,199 in the last ninety days. 4.35% of the stock is owned by corporate insiders.

Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) opened at $117.10 on Thursday. The stock has a market capitalization of $26,346.84, a price-to-earnings ratio of 59.74, a price-to-earnings-growth ratio of 1.10 and a beta of 1.16. Alexion Pharmaceuticals, Inc. has a twelve month low of $96.18 and a twelve month high of $149.34. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.10 and a quick ratio of 2.62.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.09 by $0.39. The company had revenue of $909.70 million for the quarter, compared to analysts’ expectations of $880.38 million. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. The firm’s revenue was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.26 earnings per share. equities research analysts forecast that Alexion Pharmaceuticals, Inc. will post 6.12 EPS for the current fiscal year.

Several equities research analysts recently commented on the company. BMO Capital Markets boosted their target price on Alexion Pharmaceuticals from $177.00 to $180.00 and gave the stock an “outperform” rating in a report on Friday, February 9th. Deutsche Bank set a $161.00 target price on Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, February 9th. Stifel Nicolaus reissued a “buy” rating and set a $151.00 target price on shares of Alexion Pharmaceuticals in a report on Friday, February 9th. Citigroup dropped their target price on Alexion Pharmaceuticals from $173.00 to $170.00 and set a “buy” rating on the stock in a report on Friday, February 9th. Finally, Morgan Stanley boosted their target price on Alexion Pharmaceuticals from $148.00 to $151.00 and gave the stock an “overweight” rating in a report on Friday, February 9th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and twenty-one have issued a buy rating to the company’s stock. Alexion Pharmaceuticals has a consensus rating of “Buy” and an average target price of $152.77.

TRADEMARK VIOLATION WARNING: “Alexion Pharmaceuticals, Inc. (ALXN) Stake Decreased by Itau Unibanco Holding S.A.” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.dispatchtribunal.com/2018/02/22/alexion-pharmaceuticals-inc-alxn-stake-decreased-by-itau-unibanco-holding-s-a.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply